UnknownNot Applicable

Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD

China6,000 participantsStarted 2023-01-01

Plain-language summary

Patients with PAD were grouped according to the combination of different anticoagulant and antiplate drugs. The type, dosage and duration of anticoagulant and antiplatelet drugs were recorded after operation. Major Adverse Cardiovascular Events and Major Adverse Limb Events were followed up at 1 month, 6 months and 12 months, respectively.

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age ≥50 years old
. Patients with symptomatic PAD
. Moderate intermittent claudication, or severe limb ischemia
. Radiographically confirmed occlusion
. Received a successful revascularization

Exclusion criteria

. Acute limb ischemia occurred within 2 weeks before revascularization;
. Large tissue defect of any lower limb (defined as obvious ulceration/gangrene near phalangeal head);

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 1st month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 3rd month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 6th month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 9th month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 12th month after treatment

Trial details

NCT IDNCT05852197

SponsorFirst Affiliated Hospital of Zhejiang University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-02-01

View on ClinicalTrials.gov More Anticoagulant Drugs trials

Plain-language summary

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age ≥50 years old
. Patients with symptomatic PAD
. Moderate intermittent claudication, or severe limb ischemia
. Radiographically confirmed occlusion
. Received a successful revascularization

Exclusion criteria

. Acute limb ischemia occurred within 2 weeks before revascularization;
. Large tissue defect of any lower limb (defined as obvious ulceration/gangrene near phalangeal head);

What they're measuring

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 1st month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 3rd month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 6th month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 9th month after treatment

Composite adverse event incidence (MACE/MALE) : myocardial infarction, ischemic stroke, acute limb ischemia, major amputation due to vascular disease

Timeframe: The 12th month after treatment